CJC-1295 With DAC: Mechanism, Half-Life, and Research Applications Explained

Introduction to CJC-1295 With DAC

CJC-1295 With DAC (Drug Affinity Complex) is a long-acting growth hormone-releasing hormone (GHRH) analogue widely studied in peptide and endocrine research. Engineered to extend plasma half-life and enhance molecular stability, this synthetic peptide is commonly used in experimental models investigating growth hormone (GH) pulsatility, IGF-1 regulation, and albumin-binding peptide technology.

Unlike shorter-acting GHRH analogues, CJC-1295 With DAC is designed for prolonged systemic exposure, making it particularly relevant in studies focused on sustained GH stimulation and downstream endocrine signaling.

This article is for informational and research purposes only. CJC-1295 With DAC is not approved for therapeutic or medical use.

What Is CJC-1295 With DAC?

CJC-1295 is a modified analogue of GHRH (1-29), the active fragment responsible for stimulating growth hormone release from the anterior pituitary gland.

The “With DAC” version includes a Drug Affinity Complex — a molecular modification that enables reversible binding to serum albumin. This albumin-binding capability dramatically increases the peptide’s half-life compared to native GHRH or the No DAC variant.

Key Functional Features:

• Synthetic GHRH (1-29) analogue
• Albumin-binding via Drug Affinity Complex
• Extended half-life (approximately 6–8 days in research settings)
• Sustained GH and IGF-1 elevation in experimental models

Because of this extended circulation time, CJC-1295 With DAC is often categorized as an extended-release GHRH analogue.

How the DAC Modification Extends Half-Life

The Drug Affinity Complex (DAC) attaches to specific lysine residues on the peptide, allowing reversible binding to circulating plasma albumin.

Mechanism of Action:

1. CJC-1295 binds to GHRH receptors on pituitary somatotroph cells.
2. This activates intracellular cAMP signaling pathways.
3. Growth hormone secretion is stimulated.
4. Albumin binding protects the peptide from rapid enzymatic degradation and renal clearance.

The result is prolonged systemic activity — often maintaining detectable biological effects for up to 6–8 days in controlled research models.

This pharmacokinetic profile makes it significantly longer acting than CJC-1295 No DAC, which has a much shorter half-life.

CJC-1295 With DAC vs No DAC: Key Differences

The presence of the DAC modification is the defining difference between the two variants, significantly altering pharmacokinetics and research applications.

Research Applications of CJC-1295 With DAC

In laboratory and preclinical environments, CJC-1295 With DAC is used to investigate:

• Long-term growth hormone secretion patterns
• IGF-1 expression and regulatory feedback loops
• Albumin-binding peptide pharmacodynamics
• Sustained GH pathway activation
• Comparative endocrine modeling versus short-acting GHRH analogues

Its prolonged activity makes it particularly useful for studying the effects of extended GH exposure rather than short, pulsatile stimulation.

It is important to note that CJC-1295 With DAC remains a research-use-only compound and is not approved for clinical treatment in most jurisdictions.

Stability, Storage, and Laboratory Handling

As with all synthetic research peptides, proper laboratory handling is essential for stability and reproducibility.

General Research Guidelines:

• Store lyophilized peptide at approximately −20 °C
• Store reconstituted solutions at 2–8 °C
• Use sterile technique in controlled laboratory environments
• Maintain clear labeling and documentation for compliance

Published research observations have reported transient effects such as flushing or injection-site irritation. However, these are experimental findings and do not constitute clinical safety data.

Why Researchers Study CJC-1295 With DAC

CJC-1295 With DAC demonstrates how peptide engineering can alter pharmacokinetic properties through albumin-binding modifications. By extending half-life and reducing degradation, researchers can examine:

• The relationship between sustained GH stimulation and IGF-1 levels
• Differences between acute vs prolonged endocrine activation
• Long-term signaling effects in controlled experimental models

Its design offers a clear example of how structural peptide modifications influence biological duration and systemic exposure.

Conclusion

CJC-1295 With DAC is a long-acting GHRH analogue engineered for extended systemic stability through albumin binding. In research environments, it is valued for its prolonged half-life, sustained GH stimulation, and ability to support endocrine modeling studies involving IGF-1 regulation.

While scientifically significant, CJC-1295 With DAC remains strictly a research compound and is not approved for therapeutic use. Researchers should source peptides from certified suppliers and follow institutional and regulatory guidelines for laboratory handling.